抗氧化补充剂与痴呆风险:PREADViSE试验解读
PREADViSE试验始于2002年,纳入7540名60岁以上无症状男性,随机接受维生素E、硒、二者联合或安慰剂,2009年后转为队列研究。结果显示,325/7338名男性发生痴呆(4.4%),各组发病率无差异,补充剂未预防痴呆。
要点
- 维生素E、硒单用或联用均未降低痴呆发病率。
- 痴呆发病率4.4%,组间风险比无显著差异。
- 长期使用抗氧化补充剂无痴呆预防获益。
核心结论
- 维生素E、硒单用或联用均不能预防无症状老年男性的痴呆。
研究设计与样本
- PREADViSE试验始于2002年5月,为双盲随机临床试验,2009年9月至2015年5月转为队列研究。
- 共招募7540名60岁以上男性,其中3786名继续进入队列研究,随机分为维生素E、硒、联合或安慰剂组。
- 采用改良意向性分析,使用Cox比例风险模型比较各组风险率。
主要发现
- 7338名男性中325名发生痴呆,发病率为4.4%。
- 与安慰剂相比,维生素E的风险比为0.88(95%CI,0.64-1.20),硒为0.83(0.60-1.13),联合为1.00(0.75-1.35),均无统计学显著性。
临床怎么用
- 不应推荐维生素E或硒补充剂用于预防老年男性痴呆。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia. OBJECTIVE: To determine if antioxidant supplements (vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men. DESIGN, SETTING, AND PARTICIPANTS: The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015. The PREADViSE trial was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial of the same antioxidant supplements for preventing prostate cancer, which closed in 2009 owing to findings from a futility analysis. The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study. Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and Cox proportional hazards models were used in a modified intent-to-treat analysis to compare hazard rates among the study arms. INTERVENTIONS: Participants were randomized to vitamin E, selenium, vitamin E and selenium, or placebo. While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2-stage screen. During the cohort study, men were contacted by telephone and assessed using an enhanced 2-stage cognitive screen. In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment. MAIN OUTCOMES AND MEASURES: Dementia case ascertainment relied on a consensus review of the cognitive screens and medical records for men with suspected dementia who visited their physician for an evaluation or by review of all available information, including a functional assessment screen. RESULTS: The mean (SD) baseline age of the 7540 participants was 67.5 (5.3) years, with 3936 (52.2%) reporting a college education or better, 754 (10.0%) reporting black race, and 505 (6.7%) reporting Hispanic ethnicity. Dementia incidence (325 of 7338 men [4.4%]) was not different among the 4 study arms. A Cox model, which adjusted incidence for participant demographic information and baseline self-reported comorbidities, yielded hazard ratios of 0.88 (95% CI, 0.64-1.20) for vitamin E, 0.83 (0.60-1.13) for selenium, and 1.00 (0.75-1.35) for the combination compared with placebo. CONCLUSIONS AND RELEVANCE: Neither supplement prevented dementia. To our knowledge, this is the first study to investigate the long-term association of antioxidant supplement use and dementia incidence among asymptomatic men.
引用
- Kryscio RJ, Abner EL, Caban-Holt A, et al. Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE). JAMA Neurol. 2017. PMID: 28319243. doi:10.1001/jamaneurol.2016.5778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。